Welcome to the trading week of May 9th! We are over the major earnings hump, it starts winding down here. Here is what the major components of the S&P did last week: Economic calendar:
What to Watch Monday Earnings: Teva Pharma, Sotheby's, Hertz Global, Rackspace, Liberty Broadband, SolarCity, InvenSense, International Flavors and Fragrances 5 a.m. Chicago Fed President Charles Evans 1 p.m. Minneapolis Fed President Neel Kashkari 3 p.m. San Francisco Fed President John Williams Tuesday Earnings: Disney, Electronic Arts, Nuance Communications, Planet Fitness, Norwegian Cruise Lines, Nokia, Dean Foods, Credit Suisse, Soda Stream, Lumber Liquidators 3:15 a.m. New York Fed President William Dudley 6 a.m. NFIB survey 10 a.m. Wholesale trade; JOLTs 1 p.m. $24 billion three-year note auction Wednesday Earnings: Macy's, Wendy's, Nissan, Toyota, Allianz 1 p.m. 10-year note auction 2 p.m. $23 billion federal budget Thursday Earnings: Kohl's, Nordstrom, Shake Shack, Nvidia, Party City, Ralph Lauren 8:30 a.m. Initial claims; import prices 11 a.m. Cleveland Fed President Loretta Mester 11:45 a.m. Boston Fed President Eric Rosengren 1 p.m. $15 billion 30-year bond auction 1:30 p.m. Kansas City Fed President Esther George Friday Earnings: Honda Motor, JC Penney, Brookfield Asset Management 8:30 a.m. Retail sales; PPI 10 a.m. Consumer sentiment; business inventories 6:25 p.m. San Francisco Fed's Williams http://www.cnbc.com/2016/05/06/after-fridays-jobs-shocker-this-is-what-you-need-to-watch.html
SolarCity gets upside bet before earnings optionMONSTER's market scanner detected the purchase of about 12,000 May 25 calls for $1.20 and the sale of a similar number of May 30 calls mostly for $0.41 today. Volume was far above open interest in both strikes, showing that these are new positions. http://www.optionmonster.com/news/a...y_gets_upside_bet_before_earnings_113081.html
Numbers out of China seemed good today. Let's see if these numbers reflect on direction of which stocks head this week. Their numbers beat forecast by a good 11-12%. Numbers are not great but beat forecast. http://m.investing.com/economic-calendar/chinese-trade-balance-466
Was just reading that article. Calls outnumber puts 4:1 meaning most people are bullish. Imagine a bull squeeze on that one. Did you buy any calls? I was in China recently and saw many solar manufacturers saying exports to America were hard these days to US anti-dumping taxes imposed upon them.
Now it seems like they have a different report out. http://m.investing.com/news/economi...ts,-imports-decline-more-than-expected-400605
No I didn't buy any calls. I hadn't been following SCTY. This stock is extremely oversold and if they beat there is a big upside potential.
Bloomberg been coming out with stories pieces about how consequences of negative interest rates are showing up. They take the negative slant to things.
Early movers: HCP, LC, TSN, LUV, TEVA, BRKB, DIS, FB & more http://www.cnbc.com/2016/05/09/early-movers-hcp-lc-tsn-luv-teva-brkb-dis-fb-more.html HCP — The health care real estate investment trust will spin off its HCR ManorCare portfolio into a separate, publicly traded REIT specializing in nursing and assisted living properties. Lending Club — The online lending marketplace said its CEO Renaud Laplanche had resigned after the board determined he had violated the company's business practices. He'll be replaced on an interim basis by President Scott Sanborn. Tyson Foods — Tyson earned an adjusted $1.07 per share for its latest quarter, with revenue also beating estimates. The beef and poultry producer said it was pleased with its results in what typically is the most challenging quarter of the year. Southwest Airlines — The airline reported a 4.7 percent increase in revenue passenger miles in April compared to a year ago. Southwest also had a load factor of 83.4 percent, its highest ever for April. Teva Pharmaceutical — The drugmaker earned an adjusted $1.36 per share for its latest quarter, beating estimates by 19 cents a share. Revenue also beat forecasts, with generics continuing to drive results despite no new introductions during the quarter. Berkshire Hathaway — Warren Buffett's firm missed estimates on both the top and bottom lines. Buffett had warned at last weekend's annual meeting that a slump in shipments at the company's Burlington Northern Santa Fe railroad unit would drag down results. Walt Disney — Disney's "Captain America: Civil War" topped the weekend box office with a very strong $181.8 million in North American ticket sales. That performance was the fifth-best domestic weekend opening of all time. Twitter — Twitter has cut off U.S. intelligence agencies from its service that examines its entire output, according to The Wall Street Journal. Facebook — Facebook won a court battle in China over its trademark, in a case involving a Chinese beverage company that owned the trademark "face book." Tribune Publishing — The newspaper publisher adopted a shareholder rights plan, following its rejection of Gannett's roughly $400 million takeover bid. Tribune has been urged by Oaktree Capital, its second largest shareholder, to negotiate with Gannett about a possible takeover. Oracle, Alphabet — Oracle and Alphabet's Google unit are back in court today, in a long-running copyright dispute. Oracle has accused Google of using portions of its Java software without permission. Depomed — The drugmaker may once again be a target of Horizon Pharma if Depomed is forced to put itself up for sale, according to the New York Post. Depomed successfully fought off a takeover bid from Horizon late last year. General Electric — GE will seek more acquisitions in oil and gas after the failure of Halliburton-Baker Hughes merger removed an opportunity to buy assets. Chief Financial Officer Jeff Bornstein told Bloomberg that GE had been in talks for businesses the two oilfield services giants were planning to sell.
PRESS RELEASE + OPKO Form 8K Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE® Monday, 9 May 2016 ______ - Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE® in Europe, Canada and certain other international markets - OPKO to receive up to USD 282 million in upfront and milestone payments, plus tiered double-digit royalties - OPKO and Vifor Fresenius Medical Care Renal Pharma to jointly develop RAYALDEE® for dialysis patients
Very difficult action here on the ES. Willing to stand down until something is clear vs pick a side in chop. 2048 holding so far.... *intraday commentary btw*
